Effect of nifedipine on renal allograft function and survival beyond one year

G. T. Shin, J. S. Cheigh, R. R. Riggio, Manikkam Suthanthiran, W. T. Stubenbord, D. Serur, J. C.L. Wang, A. L. Rubin, K. H. Stenzel

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We previously reported that a calcium channel blocker supplemented immunosuppression produced excellent patient and graft survival rates in cadaveric kidney transplantation. We report here the long term outcome of patients treated with nifedipine-supplemented triple immunosuppression as compared with those of historical controls who were treated similarly without nifedipine. Study subjects included 111 patients transplanted in 1990-1994, treated with nifedipine and triple immunosuppression and with functioning grafts for more than one year (Nifedipine group). The results of cyclosporine (CyA) dose, blood pressure (BP), serum creatinine (Cr), and actuarial graft survival rate (GSR) up to 5 years posttransplant in these patients were compared with those of 52 patients transplanted in 1985-1990, treated similarly without calcium channel blockers (Control group). Donor sources, gender ratio, age distribution, causes of end stage renal disease, incidence of hypertension prior to transplantation and incidence of rejection in the first year between the groups were comparabel. Throughout the study period the Nifedipine group had significantly lower serum Cr(1.5 ± 0.7 vs. 1.8 ± 0.7 mg/dl) and higher GSR (93.8% vs. 88% at 5 years) than the Control group. BP was comparable despite higher CyA doses in the Nifedipine group (4.3 ± 1.1 vs. 3.3 ± 1.1 mg/kg/day). We conclude that nifedipine is beneficial in improving long-term graft function and survival in kidney transplant recipients by mitigating CyA associated renal injury.

Original languageEnglish
Pages (from-to)33-36
Number of pages4
JournalClinical Nephrology
Volume47
Issue number1
Publication statusPublished - 7 Feb 1997
Externally publishedYes

Fingerprint

Nifedipine
Allografts
Kidney
Graft Survival
Survival
Immunosuppression
Survival Rate
Calcium Channel Blockers
Creatinine
Blood Pressure
Control Groups
Incidence
Age Distribution
Graft Rejection
Serum
Kidney Transplantation
Cyclosporine
Chronic Kidney Failure
Tissue Donors
Hypertension

Keywords

  • Allograft function and survival
  • Nifedipine
  • Renal transplantation

ASJC Scopus subject areas

  • Nephrology

Cite this

Shin, G. T., Cheigh, J. S., Riggio, R. R., Suthanthiran, M., Stubenbord, W. T., Serur, D., ... Stenzel, K. H. (1997). Effect of nifedipine on renal allograft function and survival beyond one year. Clinical Nephrology, 47(1), 33-36.

Effect of nifedipine on renal allograft function and survival beyond one year. / Shin, G. T.; Cheigh, J. S.; Riggio, R. R.; Suthanthiran, Manikkam; Stubenbord, W. T.; Serur, D.; Wang, J. C.L.; Rubin, A. L.; Stenzel, K. H.

In: Clinical Nephrology, Vol. 47, No. 1, 07.02.1997, p. 33-36.

Research output: Contribution to journalArticle

Shin, GT, Cheigh, JS, Riggio, RR, Suthanthiran, M, Stubenbord, WT, Serur, D, Wang, JCL, Rubin, AL & Stenzel, KH 1997, 'Effect of nifedipine on renal allograft function and survival beyond one year', Clinical Nephrology, vol. 47, no. 1, pp. 33-36.
Shin GT, Cheigh JS, Riggio RR, Suthanthiran M, Stubenbord WT, Serur D et al. Effect of nifedipine on renal allograft function and survival beyond one year. Clinical Nephrology. 1997 Feb 7;47(1):33-36.
Shin, G. T. ; Cheigh, J. S. ; Riggio, R. R. ; Suthanthiran, Manikkam ; Stubenbord, W. T. ; Serur, D. ; Wang, J. C.L. ; Rubin, A. L. ; Stenzel, K. H. / Effect of nifedipine on renal allograft function and survival beyond one year. In: Clinical Nephrology. 1997 ; Vol. 47, No. 1. pp. 33-36.
@article{1e8cc99054444f0491230d2c5da10762,
title = "Effect of nifedipine on renal allograft function and survival beyond one year",
abstract = "We previously reported that a calcium channel blocker supplemented immunosuppression produced excellent patient and graft survival rates in cadaveric kidney transplantation. We report here the long term outcome of patients treated with nifedipine-supplemented triple immunosuppression as compared with those of historical controls who were treated similarly without nifedipine. Study subjects included 111 patients transplanted in 1990-1994, treated with nifedipine and triple immunosuppression and with functioning grafts for more than one year (Nifedipine group). The results of cyclosporine (CyA) dose, blood pressure (BP), serum creatinine (Cr), and actuarial graft survival rate (GSR) up to 5 years posttransplant in these patients were compared with those of 52 patients transplanted in 1985-1990, treated similarly without calcium channel blockers (Control group). Donor sources, gender ratio, age distribution, causes of end stage renal disease, incidence of hypertension prior to transplantation and incidence of rejection in the first year between the groups were comparabel. Throughout the study period the Nifedipine group had significantly lower serum Cr(1.5 ± 0.7 vs. 1.8 ± 0.7 mg/dl) and higher GSR (93.8{\%} vs. 88{\%} at 5 years) than the Control group. BP was comparable despite higher CyA doses in the Nifedipine group (4.3 ± 1.1 vs. 3.3 ± 1.1 mg/kg/day). We conclude that nifedipine is beneficial in improving long-term graft function and survival in kidney transplant recipients by mitigating CyA associated renal injury.",
keywords = "Allograft function and survival, Nifedipine, Renal transplantation",
author = "Shin, {G. T.} and Cheigh, {J. S.} and Riggio, {R. R.} and Manikkam Suthanthiran and Stubenbord, {W. T.} and D. Serur and Wang, {J. C.L.} and Rubin, {A. L.} and Stenzel, {K. H.}",
year = "1997",
month = "2",
day = "7",
language = "English",
volume = "47",
pages = "33--36",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "1",

}

TY - JOUR

T1 - Effect of nifedipine on renal allograft function and survival beyond one year

AU - Shin, G. T.

AU - Cheigh, J. S.

AU - Riggio, R. R.

AU - Suthanthiran, Manikkam

AU - Stubenbord, W. T.

AU - Serur, D.

AU - Wang, J. C.L.

AU - Rubin, A. L.

AU - Stenzel, K. H.

PY - 1997/2/7

Y1 - 1997/2/7

N2 - We previously reported that a calcium channel blocker supplemented immunosuppression produced excellent patient and graft survival rates in cadaveric kidney transplantation. We report here the long term outcome of patients treated with nifedipine-supplemented triple immunosuppression as compared with those of historical controls who were treated similarly without nifedipine. Study subjects included 111 patients transplanted in 1990-1994, treated with nifedipine and triple immunosuppression and with functioning grafts for more than one year (Nifedipine group). The results of cyclosporine (CyA) dose, blood pressure (BP), serum creatinine (Cr), and actuarial graft survival rate (GSR) up to 5 years posttransplant in these patients were compared with those of 52 patients transplanted in 1985-1990, treated similarly without calcium channel blockers (Control group). Donor sources, gender ratio, age distribution, causes of end stage renal disease, incidence of hypertension prior to transplantation and incidence of rejection in the first year between the groups were comparabel. Throughout the study period the Nifedipine group had significantly lower serum Cr(1.5 ± 0.7 vs. 1.8 ± 0.7 mg/dl) and higher GSR (93.8% vs. 88% at 5 years) than the Control group. BP was comparable despite higher CyA doses in the Nifedipine group (4.3 ± 1.1 vs. 3.3 ± 1.1 mg/kg/day). We conclude that nifedipine is beneficial in improving long-term graft function and survival in kidney transplant recipients by mitigating CyA associated renal injury.

AB - We previously reported that a calcium channel blocker supplemented immunosuppression produced excellent patient and graft survival rates in cadaveric kidney transplantation. We report here the long term outcome of patients treated with nifedipine-supplemented triple immunosuppression as compared with those of historical controls who were treated similarly without nifedipine. Study subjects included 111 patients transplanted in 1990-1994, treated with nifedipine and triple immunosuppression and with functioning grafts for more than one year (Nifedipine group). The results of cyclosporine (CyA) dose, blood pressure (BP), serum creatinine (Cr), and actuarial graft survival rate (GSR) up to 5 years posttransplant in these patients were compared with those of 52 patients transplanted in 1985-1990, treated similarly without calcium channel blockers (Control group). Donor sources, gender ratio, age distribution, causes of end stage renal disease, incidence of hypertension prior to transplantation and incidence of rejection in the first year between the groups were comparabel. Throughout the study period the Nifedipine group had significantly lower serum Cr(1.5 ± 0.7 vs. 1.8 ± 0.7 mg/dl) and higher GSR (93.8% vs. 88% at 5 years) than the Control group. BP was comparable despite higher CyA doses in the Nifedipine group (4.3 ± 1.1 vs. 3.3 ± 1.1 mg/kg/day). We conclude that nifedipine is beneficial in improving long-term graft function and survival in kidney transplant recipients by mitigating CyA associated renal injury.

KW - Allograft function and survival

KW - Nifedipine

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=0031017427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031017427&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 33

EP - 36

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 1

ER -